NCT05040217View on ClinicalTrials.gov

A Clinical Trial of AAV2-BDNF Gene Therapy in Early Alzheimer's Disease and Mild Cognitive Impairment

PHASE1RecruitingINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

February 7, 2022

Primary Completion Date

December 1, 2027

Study Completion Date

December 1, 2027

Conditions
Alzheimer's DiseaseMild Cognitive Impairment
Interventions
GENETIC

AAV2-BDNF Gene Therapy

AAV2-BDNF is a genetically engineered adeno-associated virus serotype 2 (AAV-2) that expresses the human BDNF cDNA.

BIOLOGICAL

AAV2-BDNF Gene Therapy

Gene therapy is a biological therapy delivering the BDNF gene to the brain

Trial Locations (2)

43210

RECRUITING

The Ohio State University, Columbus

92093

RECRUITING

University of California - San Diego, La Jolla

All Listed Sponsors
collaborator

Ohio State University

OTHER

lead

Mark Tuszynski

OTHER